More recently, in the LuTectomy study, Eapen et al. investigated the dosimetry, safety, and efficacy of neoadjuvant [177Lu]Lu-PSMA-617 in 20 men with high-risk localized PCa with high-tumor uptake at [68Ga]Ga-PSMA-11 PET/CT before RPE. This evidence concerns the gene FOLH1 and neoplasm.